SCHEMBL928951

SCHEMBL928951

CCOC(=O)c1cc(C)c(Cl)nc1Nc1ccccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 2/20 0.46
METTL3 Q86U44 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SIRT5 Q9NXA8 1/20 0.44
CDC25A P30304 1/20 0.44
CDC25B P30305 1/20 0.44
CDC25C P30307 1/20 0.44
HTT P42858 2/20 0.43
TP53 P04637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL930913 0.86 MAP2K1 (0.55) TDP1MAPT
SCHEMBL929841 0.83 MAPT (0.51) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL930160 0.77 SYK (0.59) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL929220 0.75 MAP2K1 (0.43)
SCHEMBL28420937 0.74 POLB (0.49) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL20560379 0.73 CASP1 (0.54) SMN1; SMN2KDM4EALDH1A1MAPTTSHR
SCHEMBL1202883 0.73 CDC25B (0.52) SMN1; SMN2KDM4EALDH1A1TDP1MAPT
SCHEMBL10550202 0.72 THRB (0.53) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL3790215 0.71 PIM1 (0.50) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL28990216 0.71 ALDH1A1 (0.46) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB 2011-01-20 US disclosed
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB 2011-01-20 US disclosed
EP-2252588-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES AstraZeneca AB (SE) 2010-11-24 EP disclosed
WO-2009101432-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB (SE) 2009-08-20 WO disclosed
WO-2009101432-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB (SE) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 PDXK, MAPK1, PNPO SMN1; SMN2 2152/4885NPC1 4522/4885RAB9A 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.